tbuckley/cabot-search huggingface dataset:
FRI0100 Left Ventricular Function in Treatment-Naive Early Rheumatoid Arthritis
Authors: B.B. Løgstrup, L. Deibjerg, A. Hedemann-Kristensen, T. Ellingsen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The role of inflammation and anti-cyclic citrullinated peptide antibodies (anti-CCP) in the pathogenesis of cardiovascular disease in early rheumatoid arthritis remains unclear. <h3>Objectives</h3> We investigated how disease activity, anti-CCP status and coronary calcium score in treatment-naive early rheumatoid arthritis impacts left ventricular (LV) systolic function. <h3>Methods</h3> Fifty-tree patients with steroid- and disease-modifying antirheumatic drug-naive early rheumatoid arthritis were included. Disease activity was scored by the use of the Danish national DANBIO registry (number of swollen joints (NSJ (28)), number of tender joints (NTJ (28)), C-reactive protein (CRP) and Health Assessment Questionnaire (HAQ)). Pain, fatigue, patient and physician global assessment and a composite disease activity score (DAS28-CRP) were assessed by visual analog scales (VAS) 0-100. <h3>Results</h3> We found LV systolic function by ejection fraction to be 54.1±9.2% and to be non-significant correlated to disease activity (CRP:r=0.07,p=0.64; baseline NSJ:r=-0.13,p=0.33; NTJ:r=-0.08,p=0.58; HAQ:r=0.23,p=0.1; pain VAS:r=-0.05,p=0.74; fatigue VAS:r=0.03,p=0,83; physician global assessment:r=-0.09,p=0.54 and DAS28:r=-0.03,p=0.84). However, by global longitudinal systolic strain (GLS), we found a significant correlation: HAQ:(r=0.29;p=0.037), patient global assessment by VAS:(r=0.35;p=0.011), patient fatigue assessment by VAS:(r=0.3;p=0.03) and DAS28-CRP:(r=0.28;p=0.043); all corrected for relevant confounders. Furthermore, anti-CCP was highly significantly correlated with GLS (r= -0.44;p=0.001) in univariate analysis. In multivariate analysis, it remained significantly correlated (p=0.018). We found a significant difference in GLS in patients with high values of anti-CCP (titers ≥340) compared to patients with anti-CCP titers &lt;340); (-19.9±2.1% vs. -16.4±2.8%;p=0.0001). For patients with high IgM-RF titers results were non-significant. <h3>Conclusions</h3> We observed a significant correlation between increased disease activity and cardiac function in treatment-naive early rheumatoid arthritis. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1865
Abstract 5507: Breast cancer in Jordan: A comprehensive epidemiological analysis 1996-2008
Authors: Ahmed Salem, Abdelatief Almousa, Dania El-Tannir, Abdel-Fattah Salem
Journal: Cancer Research (2012)

Abstract Background: The epidemiology of breast cancer has been extensively studied in developed countries; however, epidemiological data is scarce in the Middle East. We present an epidemiological analysis of breast cancer in the Jordan in an attempt to aid continuously evolving strategies for cancer surveillance and control. Furthermore, we highlight the temporal changes of cancer care delivery over the period of this study. Material and methods: Data from the national cancer registry addressing the period from January 1996 to December 2008 were reviewed. The Jordanian national cancer registry was established in 1996 and utilizes a passive and active capture system. Tumor stage was classified into local, regional, distant or unknown. Crude incidence rates are expressed per 100,000. Results: Over the study years, 7,813 breast cancer cases were registered. The crude incidence rate of breast cancer ranged from 20 to 29.9 with 28.2% of cases occurring in 40-49, 26.4% of cases occuring in 50-59 and 18% of cases occuring in the 60-69 age groups. The median age was 51 (range, 16-100 years). Ductal carcinoma was found in 7,018 (89.8%), lobular adenocarcinoma in 478 (6.1%) and sarcoma in 139 (1.8%) patients. Overall; 1,412 (17.4%) cases harbored local, 1,504 (19.3%) harbored regional, 1,572 (18.3%) harbored metastatic disease while in 3,306 patients (45.2%) staging data was missing. Over the years; 2,361 (30.2%) cases were treated at academic/ comprehensive cancer centers while 4,760 (60.9%) cases were treated at a primary care/ community and/or private healthcare setting. In 692 (8.9%) patients, the location of healthcare delivery was unknown 1,652 (21.1%). We observed a trend towards referring more patients to academic/ comprehensive cancer centers over the years of the study; only 29 (6.5%) of a total of 449 patients presenting in 1996 were treated at such institutions as opposed to 406 (47.5%) of a total of 855 patients in 2008. Conclusions: This study represents the first comprehensive assessment of the epidemiological features of breast cancer in Jordan basing a framework for enhancing strategic health plans regarding cancer surveillance and control in Jordan and the Middle East. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5507. doi:1538-7445.AM2012-5507
Cost-effectiveness of FE<sub>NO</sub>-based and web-based monitoring in paediatric asthma management: a randomised controlled trial
Authors: Thijs Beerthuizen, Sandra Voorend-van Bergen, Wilbert B van den Hout, Anja A Vaessen-Verberne, Hein J Brackel, Anneke M Landstra, Norbert J van den Berg, Johan C de Jongste, Peter J Merkus, Mariëlle W Pijnenburg, Jacob K Sont
Journal: Thorax (2016)

<h3>Background</h3> In children with asthma, web-based monitoring and inflammation-driven therapy may lead to improved asthma control and reduction in medications. However, the cost-effectiveness of these monitoring strategies is yet unknown. <h3>Objective</h3> We assessed the cost-effectiveness of web-based monthly monitoring and of 4-monthly monitoring of FE<sub>NO</sub> as compared with standard care. <h3>Methods</h3> An economic evaluation was performed alongside a randomised controlled multicentre trial with a 1-year follow-up. Two hundred and seventy-two children with asthma, aged 4–18 years, were randomised to one of three strategies. In standard care, treatment was adapted according to Asthma Control Test (ACT) at 4-monthly visits, in the web-based strategy also according to web-ACT at 1 month intervals, and in the FE<sub>NO</sub>-based strategy according to ACT and FE<sub>NO</sub> at 4-monthly visits. Outcome measures were patient utilities, healthcare costs, societal costs and incremental cost per quality-adjusted life year (QALY) gained. <h3>Results</h3> No statistically significant differences were found in QALYs and costs between the three strategies. The web-based strategy had 77% chance of being most cost-effective from a healthcare perspective at a willingness to pay a generally accepted €40 000/QALY. The FE<sub>NO</sub>-based strategy had 83% chance of being most cost-effective at €40 000/QALY from a societal perspective. <h3>Conclusions</h3> Economically, web-based monitoring was preferred from a healthcare perspective, while the FE<sub>NO</sub>-based strategy was preferred from a societal perspective, although in QALYs and costs no statistically significant changes were found as compared with standard care. As clinical outcomes also favoured the web-based and FE<sub>NO</sub>-based strategies, these strategies may be useful additions to standard care. <h3>Trial registration number</h3> Netherlands Trial Register (NTR1995).
AB0406 Vitamin d cannot predict carotid subclinical atherosclerosis in sle
Authors: J.-Y. Jung, J.-Y. Jeon, B.-R. Koh, H.-A. Kim, C.-H. Suh
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Atherosclerosis in patients with systemic lupus erythematosus (SLE) develops earlier and is one of the important causes in mortality. Vitamin D was revealed to affect many systems including cardiovascular and immune system, and several data suggested vitamin D deficiency contributed cardiovascular disease and immune dysregulation in SLE. <h3>Objectives</h3> We planned to analyze correlations between vitamin D levels and carotid subclinical atherosclerosis in patients with SLE. <h3>Methods</h3> One-hundred-two female patients with SLE and 52 female normal controls were recruited. The carotid artery intima-media thickness (cIMT) and plague were assessed by B-mode ultrasound at the carotid artery level. Vitamin 25(OH)D levels were checked by immunoradiometric assay using the Bio-Line 25(OH)D3-Ria CT kit (Bio-Line S.A., Belgium). Disease activity markers were checked at the time of enrollment. <h3>Results</h3> The cIMT of SLE is 0.41 ± 0.08 mm, which is higher than normal control (0.32 ± 0.08, <i>p</i> &lt; 0.001). The carotid plague was detected in 26 patients of SLE (25.4%), and the mean of plaque index (PI) was 1.45 ± 0.14. The cIMT was correlated with age (r<sup>2</sup> = 0.458, <i>p</i> &lt; 0.001), SLEDAI (r<sup>2</sup> = 0.272, <i>p</i> = 0.028), taking aspirin or not (r<sup>2</sup> = 0.237, <i>p</i> = 0.033) in patients with SLE. The complement 3 (r<sup>2</sup> = 0.400, p = 0.010) and complement 4 (r<sup>2</sup> = -0.359, p = 0.020) were correlated with PI. The 25(OH)D levels in patients with SLE were 12.06 ± 7.56 ng/mL and 46 patients of SLE (45%) had vitamin D deficiency. The 25(OH)D levels of SLE patients were not correlated with cIMT or PI. When the patients were divided at 12 ng/mL of 25(OH)D level, only complement 4 was different significantly (18.95 ± 7.34 vs 22.27 ± 9.09, <i>p</i> = 0.047), and there was no difference in cIMT or PI between two groups. <h3>Conclusions</h3> In patients with SLE, the risk of cardiovascular disease estimated by cIMT and carotid artery plaque was higher than normal control, which was correlated with disease activity. However, vitamin D levels were not showed significant correlations with carotid subclinical atherosclerosis. To our disappointment, vitamin D level was considered inappropriate to assess predisposition to cardiovascular disease in SLE. <h3>References</h3> Wu PW, Rhew EY, Dyer AR, et al. 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum. 2009;61:1387-95. <h3>Disclosure of Interest</h3> None Declared
AB0776 Efficacy of Glucosamine Sulphate in Lowering Serum Level of Interleukin-1β in Symptomatic Primary Knee Osteoarthritis: Clinical and Laboratory Study
Authors: E. Shahine, A. Elhadidi
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Interleukin-1β (IL-1β) and other inflammatory mediators plays a pivotal role in driving the pathways associated with osteoarthritis (OA) pathogenesis and promotes cartilage degradation [1]. Glucosamine sulphate (GS) possesses anti-inflammatory efficacies against OA in animals and humans and is suggested to delay damage of cartilage and long-term progression of OA as a disease modifying anti-OA drug through its chondroprtective effect [2]. Despite the increased use of GS in the treatment of OA, the mechanisms accounting for its in vivo antiarthritic activity are still unclear. <h3>Objectives</h3> to identify the effect of α-D GS on serum level of IL-1β in patients with symptomatic primary knee OA. <h3>Methods</h3> Sixty patients (mean age=52.2±8.6 years), fulfilling the American College of Rheumatology criteria of idiopathic knee OA, were randomized to receive either 1500 mg α-D GS and 1200 mg Ibuprofen (group I), or only 1200 mg Ibuprofen (group II) daily for 12 weeks. Patients were followed up by Visual Analogue knee pain Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) functional index and quantitative detection of IL-1 β serum levels. Reference serum level of IL-1 β was determined in 20 matched healthy volunteers. <h3>Results</h3> Group I showed significant progressive improvement in pain VAS and total WOMAC scale, pain, stiffness and function subscales during the follow up visits compared to group II. At baseline, both groups had significantly higher IL-1β serum level than control group. On follow up group I showed significant progressive reduction in IL-1β serum level with a final level that was significantly lower than group II and was not significantly higher than control group. In group II the reductions in IL-1β serum level did not reach level of statistical significance and the final level persisted significantly higher than that of control group. <h3>Conclusions</h3> adding α-D GS to treatment of primary symptomatic knee OA could relieve symptoms, improve function and affect some of the disease mechanisms. <h3>References</h3> Attur M, Belitskaya-Lévy I, Oh C, et al. Increased IL-1 beta gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum 2011; 63: 1908-17. Rovati L C, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis 2012; 4: 167- 80. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1118
PREVENTABLE PRECIPITATING FACTORS OF HOSPITALIZATIONS WITH HEART FAILURE AND PROLONGED HOSPITAL LENGTH OF STAY: OBSERVATIONS FROM THE GULF CARE STUDY
Authors: Amar Salam, Kadhim Sulaiman, Jassim Al Suwaidi, Nidal Asaad, Khalid AlHabib, Wael Almahmeed, Alawi Alsheikh-Ali, Haitham Amin, Ahmed AL-Motarreb, Prashanth Panduranga, Hussam AlFaleh, Abdulfatah Elasfar, Nooshin Bazargani, Mohammad Al Jarallah, Mustafa Ridha, Awad Alqahtani, Rajvir Singh, Robert Bonow, Magdi Yacoub
Journal: Journal of the American College of Cardiology (2015)
Abstract 1498: The combination of immunosuppression and carrier cells significantly enhances poxvirus delivery and the efficacy of its oncolytic virotherapy in the pre-immunized host
Authors: Zongsheng Guo, Prag Thirunavukkarasu, Vamsi Parimi, Mark E. O'Malley, Frances Austin, Magesh Sathaiah, David L. Bartlett
Journal: Cancer Research (2010)

Abstract The pre-existing anti-poxvirus immunity in cancer patients presents a hurdle to successful poxvirus-mediated oncolytic virotherapy. To overcome this hurdle, we have explored strategies of immunosuppression (IS) or/and immune evasion (IE) for successful delivery of an oncolytic vaccinia virus to tumor models in mice pre-vaccinated with a poxvirus. These include transient IS using a cocktail of three immunosuppressive drugs (IS drugs) (tacrolimus, mycophenolate mofetil and methylprednisolone sodium succinate) that have been used in organ transplant, carrier cells as a means of IE, or the combined strategy. The three drug cocktail, which targeted multiple components of innate and adaptive immunity, displayed no enhancing effects on viral infection in tumor tissue in the pre-immunized host. Using B cell knockout mice, we confirmed that B cells and the neutralizing antibodies, the later of which were not targeted by the drug cocktail, played a significant role in preventing poxvirus infection. Cancer cells as carrier cells alone were not effective to deliver the virus to tumor. Instead, the application of both IS drugs and carrier cells worked synergistically to promote the delivery to, viral infection, replication and spread inside the tumor mass and thus enhanced the efficacy of oncolytic virotherapy in an ovarian carcinomatosis model. The administraton of these IS drugs led to facilitated development of tumor-associated macrophages (TAMs) into immunosuppressive M2 phenotype (IL-10hi/IL-12low) in the tumor microenvironment. These results revealed a novel mechanism for induction of the immunosuppressive tumor microenvironment by the IS drugs, and demonstrated in principle that it is feasible to treat pre-vaccinated cancer patients with an oncolytic poxvirus when combined with both IS and IE strategies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1498.
The US Office for Human Research Protections' intervention in the SUPPORT trial was indeed ill conceived
Authors: H. Thornton
Journal: BMJ (2013)

Neuronal damage in dorsal root ganglia (DRGs) with accompanying axonal injury is a key feature of human immunodeficiency virus (HIV)-related distal sensory polyneuropathy (DSP). In a model of HIV-related DSP, we observed numerous CD3+ T lymphocytes (<i>p</i> &lt; 0.05) in DRGs from feline immunodeficiency virus (FIV)-infected animals, which also exhibited low CD4+ and high CD8+ lymphocyte levels in blood accompanied by a selective loss of small-diameter sural nerve axons (<i>p</i> &lt; 0.05). FIV-infected lymphocytes cocultured with syngeneic DRGs caused neuronal damage, indicated by neurite retraction, neuronal soma atrophy, and loss (<i>p</i> &lt; 0.05). In contrast, supernatants from FIV-infected or uninfected lymphocytes were minimally neurotoxic, despite high FIV virion levels. Among lymphocyte subsets cocultured with DRG cultures, CD8+ T cells from both FIV-infected and uninfected lymphocytes selectively caused DRG neuronal injury (<i>p</i> &lt; 0.05). FIV-infected CD8+ T cells showed markedly increased CD154 expression (<i>p</i> &lt; 0.05), whereas neurons were the predominant cells expressing CD40 in DRGs. Blocking CD154 on activated CD8+ T cells protected DRG neurons (<i>p</i> &lt; 0.05). These findings indicated that CD8+ T cells were principal effectors of DRG neuronal injury after FIV infection through a CD40–CD154 interaction in a cell contact-dependent manner.
205 OUT-PATIENT ASSESSMENT FOR LIVER TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE
Authors: T.R. Lim, M.J. Armstrong, D.H. Houlihan, K.H. Wong, C. Cook, A. Turner, M. Perrin, J. Cantrill, P. Ashcroft, D. Hughes, C. Weijers, A. Holt
Journal: Journal of Hepatology (2012)
Abstract 4327: Fasting enhances the response of Gl26-glioma to radiation and multiple chemotherapies
Authors: Fernando Safdie, Sebastian Brandhorst, Min Wei, Weijun Wang, Changhan Lee, Saewon Hwang, Thomas Chen, Valter D. Longo
Journal: Cancer Research (2011)

Abstract Malignant gliomas like anaplastic astrocytoma and glioblastoma mutliforme (GBM) are among the most commonly diagnosed malignant adult brain tumors. GBM is highly invasive and angiogenic and causes mortality rates higher than any other brain tumor, resulting in a median survival for GBM patients that is ∼12 to 15 months. Treatment of GBM is multimodal, usually initiated by surgical resection, followed by the adjuvant therapy of radiation and chemotherapy. Temozolomide is the current standard of care for patients with newly diagnosed gliomas and is well tolerated. Temozolomide has been shown to delay tumor-progression and prolong patient survival. As the treatment of GBM remains elusive, the improvement of existing therapies becomes important. The beneficial effects of dietary restriction (DR) on reducing age-dependent diseases, such as cancer, are well established. However, DR is expected to require weeks or even months for efficacy in human patients, which eventually would prove ineffective for cancer patients with fast progressing disease status. We have previously reported that fasting, an intense but brief form of DR differentially protects normal, as opposed to various cancer cells, against the toxicity of high-dose chemotherapy in in-vitro and in-vivo in a neuroblastoma-bearing mice model by causing major changes including the reduction of glucose, and IGF-I. We termed this phenomenon Differential Stress Resistance (DSR). We show that mimicking plasma-fasting conditions in-vitro sensitizes Gl26-glioma cells to chemotherapy treatment by Temozolomide and causes enhanced cell death of the starved glioma cells. We than applied this model of sensitization of cancer cells under fasting conditions to an intracranial and a subcutaneous glioma-tumor model in-vivo. We demonstrate that short term fasting enhances chemo- and radiotherapy in the in-vivo model and prolongs survival of tumor bearing mice even when compared to Temozolomide treated animals. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4327. doi:10.1158/1538-7445.AM2011-4327
Abstract 148: Targeting DNA repair genes XRCC2 and XRCC4 with artificial miRNA sensitizes human brain tumor cells to radiation
Authors: Zhiming Zheng, Wooi Loon Ng, Ya Wang
Journal: Cancer Research (2011)

Abstract Background: Previously, we reported that targeting DNA repair genes with miR-101 could sensitize human brain tumor cells to radiation (PLoS One 5: e11397, 2010). However, some tumor cell lines with high levels of endogenous miR-101 showed less response to exogenous miR-101 (our unpublished data). To overcome the resistance of the tumors to radiation, we designed artificial miRNAs to target XRCC2 (an important factor for homologous recombination repair (HRR)) and XRCC4 (an essential factor for non-homologous end-joining (NHEJ)) because both HRR and NHEJ are required for repairing radiation-induced DNA double strand breaks (DSBs) in mammalian cells and DNA DSBs are the severest threat to cell survival. Methods: We constructed pLenti6/V5-GW/Em-GFP-miR lentiviral expression plasmids expressing artificial XRCC4 and XRCC2 miRNAs using Gateway Technology and chained artificial XRCC4 and XRCC2 miRNAs. To avoid triggering miRNA tailing and 3′-to-5′ trimming due to an extensive complementarity between a target RNA and an Argonaute1-bound miRNA, we mismatched 7 bases in the central bulge of the artificial miRNA. U87MG cells were transfected with the vector encoding both of the artificial miRNAs. XRCC4 and XRCC2 levels were measured by real-time PCR and Western blot. The effects of artificial miRNA on sensitizing U87MG cells to radiation were determined by clonogenic assay. Results: The designed artificial XRCC4/XRCC2-miRNA could be over-expressed in U87MG cells and efficiently down-regulate the XRCC4 and XRCC2 levels. Most importantly, the artificial XRCC4/XRCC2-miRNA could efficiently sensitize the brain tumor cells to radiation. Conclusion: The designed artificial miRNA targeting XRCC4 and XRCC2 could be a good tool to sensitize brain tumor cells to radiation, which provide a new approach for potentially improving radiotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 148. doi:10.1158/1538-7445.AM2011-148